Monday, October 20, 2014

TearLab reports interim results of DED prevalence study in UK

TearLab reports interim results of DED prevalence study in UK

September 4, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals.  The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. Conducted under the auspices of the UK’s National […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Mati Therapeutics isn’t your traditional biotech startup

Mati Therapeutics isn’t your traditional biotech startup

June 10, 2014 by · Leave a Comment 

Tweet Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye drops. “Because of the Phase 2 trials conducted by QLT on this technology, we have a different risk-reward profile than a […]

TearLab posts 70% jump in Q1 revenue

TearLab posts 70% jump in Q1 revenue

May 8, 2014 by · Leave a Comment 

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totaled $4.2-million, up 70%, from $2.5-million a year ago. A total of 254 orders for TearLab systems were booked in the first quarter, of which 201 systems were under the company’s Masters Multi Unit Program, 40 were through its minimum use access programs, six were direct purchases […]

In conversation with Elias Vamvakas

In conversation with Elias Vamvakas

January 28, 2014 by · Leave a Comment 

Tweet As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nanoliters of tear fluid in order to measure […]

TearLab included in Feltl’s 2014 Top Idea List

TearLab included in Feltl’s 2014 Top Idea List

January 2, 2014 by · Leave a Comment 

Tweet Feltl & Co. has released its 2014 Top Idea List, which included TearLab (NASDAQ:TEAR; TSX:TLB). Analyst Ben Haynor writes that TearLab has first-mover advantage in point-of-care diagnostics for dry eye disease (DED). The TearLab Osmolarity System is a lab-on-a-chip system that provides a quantitative measure (osmolarity) of DED in less than 30 seconds. He […]

AOA goes to bat for TearLab test with private insurers

AOA goes to bat for TearLab test with private insurers

December 20, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=p24huh7sOpI&feature=c4-overview-vl&list=PL8GkKmXDug1dWbk6nDUxsQBnR-jEi1vtr’]

Tweet The Third Party Center of the American Optometric Association has worked with several state payers to establish a favorable coverage and reimbursement policy for the diagnosis of dry eye disease using the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test. In late October, the center contacted the medical director of BlueCross BlueShield of Western New York (BCBSWNY) and BlueShield […]

TearLab osmolarity test in UK DED prevalence study

TearLab osmolarity test in UK DED prevalence study

December 17, 2013 by · Leave a Comment 

Tweet In collaboration with the UK’s National Health Service (NHS), four ophthalmologists are beginning a 1,000-patient multi-center study to assess the overall prevalence of dry eye disease (DED), using the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test for the diagnosis of DED. Patients who suffer from a wide variety of eye complications presenting daily in NHS clinics […]

TearLab added to the MSCI US Small Cap Index

TearLab added to the MSCI US Small Cap Index

November 25, 2013 by · Leave a Comment 

Tweet As a result of the November 2013 semi-annual index review for the MSCI equity indices, TearLab (NASDAQ:TEAR; TSX:TLB) will be deleted from the MSCI US Micro Cap Index and added to the MSCI US Small Cap Index after stock market close on November 26. A summary of stock deletions and additions to the MSCI equity indices can […]

Roth starts Can-Fite BioPharma at buy

Roth starts Can-Fite BioPharma at buy

October 1, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Can-Fite BioPharma (OTCQB:CANFY; TASE:CFBI) with a “buy” rating and $15 price target, suggesting investors own the stock ahead of two data readouts in the fourth quarter this year. Can-Fite is an Israeli company, whose ADRs recently started trading in the U.S. They closed at $5.03 on Monday. […]

Next Page »

Email Newsletters with Constant Contact
Google+